An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A

The primary objective of the study is to evaluate the long-term safety of recombinant human
Factor VIII Fc fusion protein (rFVIIIFc) in participants with hemophilia A. The secondary
objective of the study is to evaluate the efficacy of rFVIIIFc in the prevention and
treatment of bleeding episodes in participants with hemophilia A.